$PTI flag ( IPO ) Nasdaq GM $10.00 SEC / Edga
Post# of 23110
Posted On: 04/09/2016 8:04:08 PM
$PTI flag ( IPO )
Nasdaq GM $10.00
SEC / Edgar S-1/A
2/8/2016
Website
Shares Outstanding: 19.14M
Float: 2.83M
% Held by Insiders: 29.70%
% Held by Institutions: 0.60%
Shares Short (as of Mar 15, 2016): 16.25K
Short Ratio (as of Mar 15, 2016): 0.13
Short % of Float (as of Mar 15, 2016): 0.13%
Shares Short (prior month): 3.59K
Headlines
Proteostasis Therapeutics, Inc., a biopharmaceutical company, develops therapeutics to treat protein conformational diseases. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class. The company is also developing PTI-NC-733, a novel combination therapy; and PTI-130 for the treatment of chronic obstructive pulmonary disease. It has strategic alliance with Biogen New Ventures Inc. to enhance the clearance of misfolded aggregation-prone proteins in neurodegenerative diseases, such as in Alzheimers and Parkinsons disease; and Astellas Pharma Inc. to research, develop, and commercialize therapies targeting unfolded protein response. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.
Nasdaq GM $10.00
SEC / Edgar S-1/A
2/8/2016
Website
Shares Outstanding: 19.14M
Float: 2.83M
% Held by Insiders: 29.70%
% Held by Institutions: 0.60%
Shares Short (as of Mar 15, 2016): 16.25K
Short Ratio (as of Mar 15, 2016): 0.13
Short % of Float (as of Mar 15, 2016): 0.13%
Shares Short (prior month): 3.59K
Headlines
Proteostasis Therapeutics, Inc., a biopharmaceutical company, develops therapeutics to treat protein conformational diseases. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class. The company is also developing PTI-NC-733, a novel combination therapy; and PTI-130 for the treatment of chronic obstructive pulmonary disease. It has strategic alliance with Biogen New Ventures Inc. to enhance the clearance of misfolded aggregation-prone proteins in neurodegenerative diseases, such as in Alzheimers and Parkinsons disease; and Astellas Pharma Inc. to research, develop, and commercialize therapies targeting unfolded protein response. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.
(1)
(0)